Transcatheter Arterial Chemoembolization with Paclitaxel-Lipiodol Solution in Rabbit VX2 Liver Tumor
Authors:
- Jin Wook ChungJCJin Wook Chung
- Jae Hyung ParkJPJae Hyung Park
- Young Ho YoonYYYoung Ho Yoon
- Joon Woo LeeJLJoon Woo Lee
- Seo Young JeongSJSeo Young Jeong
- Hesson ChungHCHesson Chung
- 1 October 2003
- journal article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 229 (1) , 126-131
Abstract
To evaluate the antitumor effects of transcatheter arterial chemoembolization (TACE) with a solution of an anticancer drug (Paclitaxel; Bristol-Myers Squibb, Princeton, NJ) and iodized oil (Lipiodol; Laboratoire Gurerbet, Aulnay-Sous-Bois, France) (hereafter, the solution), as well as intratumor concentration and hepatotoxicity, in experimentally induced liver tumor. VX2 carcinoma was grown in livers of 30 rabbits. In 18 rabbits, TACE was performed with the high-dose solution (4 mg anticancer drug and 0.4 mL iodized oil, n = 6), the low-dose solution (1 mg anticancer drug and 0.4 mL iodized oil, n = 6), or iodized oil alone (0.4 mL, n = 6) in a control group. One week later, the growth ratio and residual viable proportion of the tumors were calculated on the basis of findings at spiral computed tomography and histopathologic examination. Hepatic and hematologic toxicities were evaluated by means of biochemical analysis. Differences between the three groups were statistically assessed with the Kruskal-Wallace and Mann-Whitney U tests. The remaining 12 animals were treated with the high-dose solution and serially sacrificed for clarification of chronologic change of concentration of the anticancer drug in liver tissues. Growth ratios and residual viable proportions of the tumors were significantly lower in the solution groups (high dose, 3.3% +/- 6.2 [mean +/- SD] and 2.8% +/- 3.6, respectively; low dose, 18.7% +/- 7.4 and 12.7% +/- 6.1, respectively) than in the control group (68.3% +/- 12.7 and 31.1% +/- 8.8, respectively) (P <.05). Hepatotoxicity was transient in all but one rabbit, which died 2 days after TACE with substantial biochemical changes. The anticancer drug accumulated in tumor where the concentration peaked at day 3 and returned to levels comparable to those for normal hepatic parenchyma at 7 days after TACE. TACE with the Paclitaxel-Lipiodol solution has dose-dependent antitumor effects without major toxicities in VX2 liver tumor.Keywords
This publication has 19 references indexed in Scilit:
- Hepatic Artery Administration of PaclitaxelCancer Investigation, 1999
- Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1995
- Antitumor Effects of Intraarterial Infusion of Tumor Necrosis Factor/Lipiodol Emulsion on Hepatic Tumor in RabbitsOncology, 1995
- High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol®) in human plasmaJournal of Chromatography B: Biomedical Sciences and Applications, 1993
- Transcatheter hepatic segmental arterial embolization using lipiodol mixed with an anticancer drug and gelfoam particles for hepatocellular carcinomaCardioVascular and Interventional Radiology, 1990
- Treatment of hepatocellular carcinoma by segmental hepatic artery injection of adriamycin-in-oil emulsion with overflow to segmental portal veinsActa Radiologica, 1990
- A 5-year experience of lipiodolization: Selective regional chemotherapy for 200 patients with hepatocellular carcinomaHepatology, 1989
- A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin spongeCancer, 1987
- Taxol stabilizes microtubules in mouse fibroblast cells.Proceedings of the National Academy of Sciences, 1980
- Promotion of microtubule assembly in vitro by taxolNature, 1979